ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 8.5% in December

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 2,150,000 shares, a drop of 8.5% from the December 15th total of 2,350,000 shares. Based on an average daily trading volume, of 252,300 shares, the days-to-cover ratio is currently 8.5 days.

ANI Pharmaceuticals Trading Up 1.7 %

Shares of NASDAQ:ANIP opened at $58.46 on Monday. The company has a market capitalization of $1.23 billion, a PE ratio of -106.29 and a beta of 0.73. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.81. The business’s fifty day simple moving average is $56.36 and its 200-day simple moving average is $58.80.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same period in the previous year, the company posted $1.05 earnings per share. The firm’s revenue was up 12.5% on a year-over-year basis. As a group, equities research analysts predict that ANI Pharmaceuticals will post 3.87 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of recent analyst reports. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $77.71.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. This trade represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,381 shares of company stock worth $2,441,556 over the last three months. 12.70% of the stock is owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Pacer Advisors Inc. raised its stake in ANI Pharmaceuticals by 23,259.8% in the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after buying an additional 565,910 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after acquiring an additional 340,854 shares in the last quarter. Bank of Montreal Can purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $13,043,000. Millennium Management LLC boosted its stake in ANI Pharmaceuticals by 1,005.8% in the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock worth $14,651,000 after purchasing an additional 209,272 shares in the last quarter. Finally, Mizuho Markets Americas LLC purchased a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $11,670,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.